United States Biotechnology & Medical Research

Braveheart Bio, Inc. (BRVE)

Track

Track

Braveheart Bio experienced significant insider trading activity on August 7, 2026, with ten individuals and entities executing thirteen buy transactions totaling approximately $159 million. These acquisitions occurred despite a 2% decline in stock value over the last quarter and a recent earnings report showing a substantial miss in expected performance metrics.
Ticker: BRVE Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
AH Bio Fund IV, L.P. Large shareholder
Transaction date
Purchase
Price
250.20
Quantity 35,375 +10.7%
Value US$3,754,794
Chimovits Erez Non-Executive Director Large shareholder
Transaction date
Purchase
Price
53.08
Quantity 77,482 -9.9%
Value US$2,747,465
Chimovits Erez Non-Executive Director Large shareholder
Transaction date
Purchase
Price
383.18
Quantity 53,520 -0.1%
Value US$1,212,891
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 273,333 +inf%
Value US$4,919,994
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 1,666,667 +16.3%
Value US$30,000,006
3.3
Rickey James Paul Chief Financial Officer Officer
Transaction date
Purchase
Price
18.00
Quantity 27,777 +5.6%
Value US$499,986
2.2
Lubner David Charles Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 55,555 +inf%
Value US$999,990
Murdoch Travis CEO and President Executive Director
Transaction date
Purchase
Price
18.00
Quantity 83,333 +2.9%
Value US$1,499,994
Anderson Michele A. Chief Development Officer Officer
Transaction date
Purchase
Price
18.00
Quantity 1,111 +0.3%
Value US$19,998
2.9
Viehbacher Christopher Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 83,333 +15.8%
Value US$1,499,994
Malek David I Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 4,166 +0.8%
Value US$74,988
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-11 2026-08-07 B Purchase
AH Bio Fund IV, L.P.
Large shareholder
35,375 +10.7%
250.20
US$3,754,794 		35,375 +10.7% 250.20 US$3,754,794
2026-08-11 2026-08-07 B Purchase
Chimovits Erez
Non-Executive Director Large shareholder
77,482 -9.9%
53.08
US$2,747,465 		77,482 -9.9% 53.08 US$2,747,465
2026-08-11 2026-08-07 B Purchase
Chimovits Erez
Non-Executive Director Large shareholder
53,520 -0.1%
383.18
US$1,212,891 		53,520 -0.1% 383.18 US$1,212,891
2026-08-11 2026-08-07 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
273,333 +inf%
18.00
US$4,919,994 		273,333 +inf% 18.00 US$4,919,994
2026-08-11 2026-08-07 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,666,667 +16.3%
18.00
US$30,000,006 		1,666,667 +16.3% 18.00 US$30,000,006
2026-08-07 2026-08-07 B Purchase
Forbion Growth Opportunities Fund III Cooperatief U.A.
Large shareholder
1,680,000 +19.8%
18.00
US$30,240,000 		1,680,000 +19.8% 18.00 US$30,240,000
2026-08-07 2026-08-07 B Purchase
Forbion Growth Opportunities Fund III Cooperatief U.A.
Large shareholder
1,920,000 +19.8%
18.00
US$34,560,000 		1,920,000 +19.8% 18.00 US$34,560,000
2026-08-07 2026-08-07 B Purchase
3.3
Rickey James Paul

Chief Financial Officer

Officer
27,777 +5.6%
18.00
US$499,986 		27,777 +5.6% 18.00 US$499,986
2026-08-07 2026-08-07 B Purchase
2.2
Lubner David Charles
Non-Executive Director
55,555 +inf%
18.00
US$999,990 		55,555 +inf% 18.00 US$999,990
2026-08-07 2026-08-07 B Purchase
Murdoch Travis

CEO and President

Executive Director
83,333 +2.9%
18.00
US$1,499,994 		83,333 +2.9% 18.00 US$1,499,994
2026-08-07 2026-08-07 B Purchase
Anderson Michele A.

Chief Development Officer

Officer
1,111 +0.3%
18.00
US$19,998 		1,111 +0.3% 18.00 US$19,998
2026-08-07 2026-08-07 B Purchase
2.9
Viehbacher Christopher
Non-Executive Director
83,333 +15.8%
18.00
US$1,499,994 		83,333 +15.8% 18.00 US$1,499,994
2026-08-07 2026-08-07 B Purchase
Malek David I
Non-Executive Director
4,166 +0.8%
18.00
US$74,988 		4,166 +0.8% 18.00 US$74,988
Explore more

More insider trading research around Braveheart Bio, Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America